Fosun Pharma sees Q3 2025 profit growth despite revenue dip

Shanghai Fosun Pharmaceutical (Group) Co. announced its 2025 Third Quarterly Report, revealing a net profit attributable to shareholders of 821,325,734.40 yuan for the three months ended September 30, 2025, a 4.52% increase year-on-year. Basic and diluted earnings per share also rose to 0.31 yuan, up 6.90%. Net cash flow from operating activities grew by 15.57% to 1,247,768,071.40 yuan for the quarter. For the first nine months of 2025, total profit increased by 24.93% to 3,837,343,481.79 yuan.

Despite these gains, operating revenue for the third quarter decreased by 5.46% to 9,878,953,511.32 yuan, and by 4.91% to 29,393,385,360.91 yuan for the first nine months. This decline was primarily attributed to the renewal of national and regional volume-based drug procurement contracts. However, revenue from innovative drugs showed steady growth, exceeding 6,700 million yuan, an 18.09% period-on-period increase for the first nine months of 2025.

The company continued its focus on R&D, with investments totaling 3,998 million yuan for the first nine months, a 2.12% increase year-on-year. Key R&D achievements included the approval of Fu Tuo Ning for a new indication in China, the overseas launch approval for Denosumab Injection (HLX14) in the US and EU, and the submission of Brexucabtagene Autoleucel Injection (FKC889) for launch in Chinese mainland. The company also established a radiotherapy business platform, Chengdu Xingrui Jingxuan Therapeutics Company Limited, to expand into pan-tumor theranostics.